Publication
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Journal Paper/Review - Jul 28, 2017
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Units
PubMed
Doi
Citation
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Type
Journal Paper/Review (English)
Journal
Blood Cancer J 2017; 7
Publication Date
Jul 28, 2017
Issn Electronic
2044-5385
Pages
e589